CoChat
Sign Up
Cited by 630Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: The TEAM-AD VA Cooperative Randomized Trial

Open access
Dysken, Maurice W., Sano, Mary, Asthana, Sanjay, Vertrees, Julia E., Pallaki, Muralidhar, Llorente, Maria, Love, Susan, Schellenberg, Gerard D., McCarten, J. Riley, Malphurs, Julie, Prieto, Susana, Chen, Peijun, Loreck, David J., Trapp, George, Bakshi, Rajbir S., Mintzer, Jacobo E., Heidebrink, Judith L., Vidal-Cardona, Ana, Arroyo, Lillian M., Cruz, Angel R., Zachariah, Sally, Kowall, Neil W., Chopra, Mohit P., Craft, Suzanne, Thielke, Stephen, Turvey, Carolyn L., Woodman, Catherine, Monnell, Kimberly A., Gordon, Kimberly, Tomaska, Julie, Segal, Yoav, Peduzzi, Peter N., Guarino, Peter D.·2014·JAMA
DOI 10.1001/jama.2013.282834PMC PMC4109898
Open this paper in CoChat — free account

Abstract

IMPORTANCE: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD. OBJECTIVE: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, parallel-group, randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers. INTERVENTIONS: Participants received either 2000 IU/d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152). MAIN OUTCOMES AND MEASURES: Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver measures. RESULTS: Data from 561 participants were analyzed (alpha tocopherol = 140, memantine = 142, combination = 139, placebo = 140), with 52 excluded because of a lack of any follow-up data. Over the mean (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.92 to 5.39; adjusted P = .03) less in the alpha tocopherol group compared with the placebo group. In the memantine group, these scores declined 1.98 units less (95% CI, -0.24 to 4.20; adjusted P = .40) than the placebo group's decline. This change in the alpha tocopherol group translates into a delay in clinical progression of 19% per year compared with placebo or a delay of approximately 6.2 months over the follow-up period. Caregiver time increased least in the alpha tocopherol group. All-cause mortality and safety analyses showed a difference only on the serious adverse event of "infections or infestations," with greater frequencies in the memantine (31 events in 23 participants) and combination groups (44 events in 31 participants) compared with placebo (13 events in 11 participants). CONCLUSIONS AND RELEVANCE: Among patients with mild to moderate AD, 2000 IU/d of alpha tocopherol compared with placebo resulted in slower functional decline. There were no significant differences in the groups receiving memantine alone or memantine plus alpha tocopherol. These findings suggest benefit of alpha tocopherol in mild to moderate AD by slowing functional decline and decreasing caregiver burden. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00235716.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2013.282834

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

See all 630

Related

See all

Metadata

Authors
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., Prieto, S., Chen, P., Loreck, D. J., Trapp, G., Bakshi, R. S., Mintzer, J. E., Heidebrink, J. L., Vidal-Cardona, A., Arroyo, L. M., Cruz, A. R., Zachariah, S., Kowall, N. W., Chopra, M. P., Craft, S., Thielke, S., Turvey, C. L., Woodman, C., Monnell, K. A., Gordon, K., Tomaska, J., Segal, Y., Peduzzi, P. N., & Guarino, P. D.
Affiliations
  • Minneapolis VA Health Care System (US)
  • James J. Peters VA Medical Center (US)
  • William S. Middleton Memorial Veterans Hospital (US)
  • Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico
  • Louis Stokes Cleveland VA Medical Center (US)
  • Washington DC VA Medical Center (US)
  • University of Pennsylvania (US)
  • Miami VA Healthcare System (US)
  • VA Maryland Health Care System (US)
  • VA North Texas Health Care System (US)
  • Medical University of South Carolina (US)
  • VA Ann Arbor Healthcare System (US)
  • VA Caribbean Healthcare System, San Juan, Puerto Rico
  • VA Caribbean Healthcare System (PR)
  • Bay Pines VA Healthcare System (US)
  • VA Boston Healthcare System (US)
  • University of Washington (US)
  • University of Iowa (US)
  • W. G. (Bill) Hefner VA Medical Center (US)
  • Yale University (US)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2014-01-01
Volume
311
Issue
1
Pages
33
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2013.282834
PMC
PMC4109898
OpenAlex
W2128047032
Cited by
628
References
40
Citations by year
2026: 34 · 2025: 41 · 2024: 36 · 2023: 54 · 2022: 56 · 2021: 53 · 2020: 47 · 2019: 47 · 2018: 61 · 2017: 48 · 2016: 50 · 2015: 55 · 2014: 44
FWCI
35.66
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Aging (P50AG005138, P30AG013846, P50AG005136)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, vitamin E, alpha-tocopherol, memantine, functional decline, activities of daily living, acetylcholinesterase inhibitors, disease progression, caregiver burden, neuropsychiatric symptoms, adverse events, infections and infestations, combination therapy, veterans, older adults, cognitive decline, mortality, quality of life, cost-effectiveness
MeSH terms
Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Antioxidants, Cholinesterase Inhibitors, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Memantine, Middle Aged, Severity of Illness Index, Vitamin E, Dopamine Agents, Treatment Outcome, Caregivers, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review